KR20120094472A - 신규한 복용 요법 및 치료 방법 - Google Patents

신규한 복용 요법 및 치료 방법 Download PDF

Info

Publication number
KR20120094472A
KR20120094472A KR1020127008847A KR20127008847A KR20120094472A KR 20120094472 A KR20120094472 A KR 20120094472A KR 1020127008847 A KR1020127008847 A KR 1020127008847A KR 20127008847 A KR20127008847 A KR 20127008847A KR 20120094472 A KR20120094472 A KR 20120094472A
Authority
KR
South Korea
Prior art keywords
days
weeks
administered
cancer
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127008847A
Other languages
English (en)
Korean (ko)
Inventor
존 램버트
제임스 제이. 올리어리
죠앤 엘리자베스 사라 쉰들러
스티븐 웨이트먼
앨버트 친
Original Assignee
이뮤노젠 아이엔씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤노젠 아이엔씨 filed Critical 이뮤노젠 아이엔씨
Publication of KR20120094472A publication Critical patent/KR20120094472A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127008847A 2009-10-21 2010-10-21 신규한 복용 요법 및 치료 방법 Withdrawn KR20120094472A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25380409P 2009-10-21 2009-10-21
US61/253,804 2009-10-21

Publications (1)

Publication Number Publication Date
KR20120094472A true KR20120094472A (ko) 2012-08-24

Family

ID=43898626

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127008847A Withdrawn KR20120094472A (ko) 2009-10-21 2010-10-21 신규한 복용 요법 및 치료 방법

Country Status (13)

Country Link
US (1) US20110097345A1 (cg-RX-API-DMAC7.html)
EP (1) EP2490715A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013508400A (cg-RX-API-DMAC7.html)
KR (1) KR20120094472A (cg-RX-API-DMAC7.html)
CN (1) CN102630165A (cg-RX-API-DMAC7.html)
AU (1) AU2010310577A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012009250A2 (cg-RX-API-DMAC7.html)
CA (1) CA2775806A1 (cg-RX-API-DMAC7.html)
IL (1) IL219279A0 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN02826A (cg-RX-API-DMAC7.html)
MX (1) MX2012004406A (cg-RX-API-DMAC7.html)
RU (1) RU2012120691A (cg-RX-API-DMAC7.html)
WO (1) WO2011050180A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CN102812041A (zh) * 2010-01-21 2012-12-05 英穆尔诺基公司 治疗卵巢癌的组合物及方法
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014052876A1 (en) * 2012-09-28 2014-04-03 Immunogen Inc. Methods for increasing efficacy of cd56- based therapy
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
KR20240068778A (ko) * 2013-05-14 2024-05-17 이뮤노젠 아이엔씨 항-folr1 면역접합체 투약 섭생
SG10202102555TA (en) * 2013-10-08 2021-04-29 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
CA2954934C (en) 2014-06-30 2023-09-26 Glykos Finland Oy Drug derivative and conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP4286381A3 (en) * 2016-08-10 2024-02-28 Celgene Quanticel Research, Inc. Treatment of merkel celll carcinoma
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
AU2019294510A1 (en) * 2018-06-26 2021-01-21 Immunogen, Inc. Immunoconjugates targeting ADAM9 and methods of use thereof
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
KR20230038180A (ko) * 2020-06-04 2023-03-17 바이오인벤트 인터내셔날 에이비 정맥 내 투여와 관련된 항체 관용성 개선
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN121152872A (zh) * 2023-05-10 2025-12-16 南京传奇生物科技有限公司 嵌合抗原受体及其使用方法
CN120053673A (zh) * 2025-02-11 2025-05-30 暨南大学 纳米前药及其制备方法和用途
CN120173115A (zh) * 2025-05-20 2025-06-20 苏州欣协生物科技有限公司 一种抗人cd56蛋白工程抗体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
HK1049787B (en) * 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) * 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2452288A1 (en) * 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
KR101424624B1 (ko) * 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US20060281813A1 (en) * 2003-06-05 2006-12-14 Charles Rubin Methods of treating hyperproliferative cell disorders
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
EP3753576A1 (en) * 2006-09-26 2020-12-23 Genmab A/S Combination treatment of cd38-expressing tumors
CA2727278A1 (en) * 2008-06-16 2010-01-21 Immunogen, Inc. Novel synergistic effects
CN102812041A (zh) * 2010-01-21 2012-12-05 英穆尔诺基公司 治疗卵巢癌的组合物及方法
AU2012240448A1 (en) * 2011-04-01 2013-03-28 Immunogen, Inc. Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer

Also Published As

Publication number Publication date
IN2012DN02826A (cg-RX-API-DMAC7.html) 2015-07-24
CN102630165A (zh) 2012-08-08
EP2490715A4 (en) 2013-06-26
WO2011050180A1 (en) 2011-04-28
BR112012009250A2 (pt) 2017-06-20
CA2775806A1 (en) 2011-04-28
RU2012120691A (ru) 2013-11-27
IL219279A0 (en) 2012-06-28
AU2010310577A1 (en) 2012-04-19
EP2490715A1 (en) 2012-08-29
JP2013508400A (ja) 2013-03-07
US20110097345A1 (en) 2011-04-28
MX2012004406A (es) 2012-05-08

Similar Documents

Publication Publication Date Title
KR20120094472A (ko) 신규한 복용 요법 및 치료 방법
Trail et al. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design
AU2016216585B2 (en) Drug conjugate composition
US20230110128A1 (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
JP2007500236A (ja) 組換え抗ｃｄ３０抗体とその使用
EP1531869A2 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immunoconjugates and chemotherapeutic agents
CN101237881B (zh) 免疫偶联物剂型
Tumey Next generation payloads for ADCs
CN116490213A (zh) 用于治疗癌症的人源化抗liv1抗体
HK1174551A (en) Novel dosing regimen and method of treatment
Shao et al. Research and development of highly potent antibody-based drug conjugates and fusion proteins for cancer therapy
WO2024194775A1 (en) Sacituzumab drug conjugates and preparation thereof
HK40044344A (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
EA046736B1 (ru) Фармацевтические комбинации
Perrino Non-Internalizing Antibody-Drug Conjugates for Cancer Therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000